PRESS RELEASE published on 04/29/2026 at 13:39, 6 months 12 days ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
PRESS RELEASE published on 04/29/2026 at 13:39, 6 months 12 days ago Informations privilégiées / Autres communiqués Medincell annonce une forte croissance des ventes de UZEDY aux Etats-Unis, une formulation injectable approuvée par la FDA pour la schizophrénie et le trouble bipolaire. De nouvelles avancées pour l'olanzapine LAI sont également en cours FDA Schizophrénie Medincell Teva UZEDY
BRIEF published on 04/20/2026 at 11:18, 6 months 21 days ago Franchissement de seuil par BNP Paribas Développement chez MEDINCELL Euronext Paris Droits De Vote Franchissement De Seuil BNP Paribas Medincell
BRIEF published on 04/20/2026 at 11:18, 6 months 21 days ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
PRESS RELEASE published on 04/20/2026 at 11:13, 6 months 21 days ago Franchissement de seuil Déclaration de franchissement de seuil par BNP Paribas Développement concernant MEDINCELL sur Euronext Paris Euronext Paris Droits De Vote Franchissement De Seuil Medincell BNP Paribas Développement
BRIEF published on 04/02/2026 at 19:05, 7 months 9 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
BRIEF published on 04/02/2026 at 19:05, 7 months 9 days ago Medincell : Mise à jour sur le capital et les droits de vote Droits De Vote Euronext Capital Social Actions AMF
PRESS RELEASE published on 04/02/2026 at 19:00, 7 months 9 days ago Informations privilégiées / Autres communiqués Euronext MEDCL divulgue les chiffres du capital social et des droits de vote conformément au règlement de l'AMF. Medincell développe des traitements biopharmaceutiques innovants à action prolongée Droits De Vote Euronext Capital Social Medincell MEDCL
BRIEF published on 02/20/2026 at 21:42, 8 months 18 days ago La suspension injectable d'olanzapine de Teva obtient l'approbation de la FDA Schizophrénie Olanzapine Teva Pharmaceuticals Acceptation Par La FDA Injectable À Action Prolongée
BRIEF published on 02/20/2026 at 21:42, 8 months 18 days ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
Published on 11/11/2026 at 19:31, 1 hour 35 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 4 hours 36 minutes ago ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 6 hours 41 minutes ago Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 7 hours 6 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 7 hours 6 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 19:29, 1 hour 37 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 2 hours 24 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 3 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 3 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 3 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 3 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
